A phase 3 trial evaluating the efficacy and safety of rivaroxaban (Xarelto, Bayer/Janssen), an oral anticoagulant, for the prevention of major adverse cardiac events (MACE) – including cardiovascular death, myocardial infarction, and stroke – in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint. The COMPASS trial enrolled 27,402 patients in more than 30 countries worldwide. The patients were randomly assigned to receive either rivaroxaban 2.5 mg twice daily in addition to aspirin 100 mg once daily; rivaroxaban 5.0 mg twice daily alone; or aspirin 100 mg once daily alone.

Read More